To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2017 News Releases

About RSS

Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Quetiapine Fumarate in Japan

February 27, 2017

Kyowa Pharmaceutical Industry Co., Ltd. (Head office: Yodogawa-ku, Osaka City, President and Representative Director: Ray Tsunoda, hereinafter called “Kyowa”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the companies have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan. Astellas submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder.

 

When Astellas obtains an approval for the new drug application of extended-release tablets of quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan.

 

###

 

Printer-friendly version


Main Text end
Local Navigation
Local Navigation end
Related Links